

Année 2010

-

Travaux :

Service d'Hématologie Clinique et Thérapie Cellulaire
& Unité de Recherche Clinique Hématologie

-

Réseau Hématolim

✓ Publications

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.

Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, Leblond V, Roussel M, Alakl M, Hermine O, Planche L, Harousseau JL, Feraud JP.
Blood. 2010, 116(23):4777-82.

Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.

Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germe R, Pillet S, Lebranchu Y, Turlure P, Alain S; French CMV Resistance Survey Study Group.
J Antimicrob Chemother. 2010, 65(12):2628-40.

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).
Blood. 2010,116(19):3735-42.

Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.

Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus.
Leuk Res. 2010, 34(11):1430-6.

Involvement of Human Herpesvirus-6 Variant B in Classic Hodgkin's Lymphoma via DR7 Oncoprotein.

Lacroix A, Collot-Teixeira S, Mardivirin L, Jaccard A, Petit B, Pigué C, Sturtz F, Preux PM, Bordessoule D, Ranger-Rogez S.
Clin Cancer Res. 2010,16(19):4711-21.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H.
Blood. 2010,116(12):2040-5.

Endonasal trans-ethmoidal drainage of a cerebral abscess.

Patron V, Orsel S, Caire F, Turlure P, Bessède JP, Aubry K.
Skull Base. 2010, 20(5):389-92.

Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.

Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, **Girault S**, **Gachard N**, Tigaud I, Dastugue N, Huguet F, Fort MP, Legros L, Eclache V, Mahon FX. *Haematologica*. 2010, 95(9):1604-7.

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, **Bordessoule D**, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C. *J Clin Oncol*. 2010, 28(23):3717-23.

Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial.

Chevallier P, Fomecker L, Lioure B, Béné MC, Pigneux A, Recher C, Witz B, Fegueux N, Bulabois CE, Daliphard S, Bouscary D, Vey N, Delain M, Bay JO, **Turlure P**, Bernard M, Himberlin C, Luquet I, Ifrah N, Harousseau JL; GOELAMS. *Leukemia*. 2010, 24(7):1380-5.

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, **Chaury MP**, Roy L, Cheze S, Morel P, Fenaux P; GFM (Groupe Francophone des Myélodysplasies). *Leuk Res*. 2010, 34(7):864-70.

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.

Kelaidi C, Stamatoullas A, Beyne-Rauzy O, Raffoux E, Quesnel B, Guerci A, Dreyfus F, Brechignac S, Berthou C, Prebet T, Hicheri Y, Hacini M, Delaunay J, **Gourin MP**, Camo JM, Zerazhi H, Taksin AL, Legros L, Choufi B, Fenaux P; Groupe Francophone des Myélodysplasies. *Haematologica*. 2010, 95(6):892-9.

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.

Raffoux E, Cras A, Recher C, Boëlle PY, de Labarthe A, **Turlure P**, Marolleau JP, Reman O, Gardin C, Victor M, Maury S, Rousselot P, Malfuson JV, Maarek O, Daniel MT, Fenaux P, Degos L, Chomienne C, Chevret S, Dombret H. *Oncotarget*. 2010, 1(1):34-42.

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience

Coppo P, Schwarzingler M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, **Girault S**, **Bordessoule D**, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A; French Reference Center for Thrombotic Microangiopathies. *PLoS One*. 2010, 5(4).

Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma

Troutaud D, Petit B, Bellanger C, Marin B, Gourin-Chaury MP, Petit D, Olivrie A, Feuillard J, Jauberteau MO, Bordessoule D.
Clin Lymphoma Myeloma Leuk. 2010, 10(2):118-24.

Very long-term outcome of acute promyelocytic leukemia after treatment with all trans retinoic acid and chemotherapy: the European APL Group experience.

Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P; European APL Group
Blood. 2010, 115(9):1690-6.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.

Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rouselot P, Preudhomme C, Bordessoule D, Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S.
J Clin Oncol. 2010, 28(5):808-14.

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prirituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte

Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-Celigny P, Salles G.
J Clin Oncol. 2010, 28(5):822-9.

La réflexion collective sur le sens du soin : une dimension essentielle en hématologie

Bordessoule D

Hématologie, 2010, 16 (1) :80.

Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation.

Chevallier P, Prebet T, Turlure P, Hunault M, Vigouroux S, Harousseau JL, Blaise D, Ifrah N, Milpied N, Mohty M.
Bone Marrow Transplant. 2010, 45(1):165-70.

✓ **Communications orales et posters dans les congrès nationaux ou internationaux**

Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study

De Renzis B, Wattel E, Beyne-Rauzy O, Knoops L, Boyer F, Cabrespine A, Raynaud S, Rose C, Demory JL, Nguyen-Khac F, Ades L, Tertian G, Guièze R, Ianotto JC, Tournilhac O, Bordessoule D, Cahn JY, Fontenay M, Kiladjian JJ, Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 440.

Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group

Ades L, Raffoux E, Chevret S, Pigneux A, Thomas X, Bordessoule D, Vey N, Guerci A, Lamy T, Récher C, Muller B, Tournilhac O, Pautas C, Cahn JY, Delaunay J, Deconinck E, Quesnel B, de Botton S, Stamatoullas A, Chomienne C, Dombret H, Degos L, Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 505.

Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B

Peyrade F, Jardin F, Gisselbrecht C, hyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, Bosly A, Tilly H.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 853.

High Body Mass Index (BMI) as a Predictor of Differentiation Syndrome (DS) In Acute Promyelocytic Leukemia (APL)

Jeddi R, Achour B, Guerci-Bresler A, Ghédira H, Dombret H, Huguet F, Chevallier P, Vey N, de Botton S, Bordessoule D, Muller B, Eclache V, Gardin C, Meddeb B, Adès L, Pierre Fenaux P.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 1078

Use of Cytarabine for Mantle Cell Lymphoma Treatment: 10 Years of Experience of a French Haematology Department

Gourin MP, Abraham A, Trimoreau F, Petit B, Girault S, Olivrie A, Jaccard A, Feuillard J, Bordessoule D.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts) 2010; 116: 1755.

Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS ?

Cereja S, Brechignac S, Ades L, Braun T, Boehrer S, Hebibi Z, Sapena R, Beyne-Rauzy O, Vey N, Dombret H, Bordessoule D, Dreyfus F, Fenaux P, Gardin C.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 1868.

Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases

Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Vey N, Guerci A, Lamy T, Récher C, Mueller B, Tournilhac O, Pautas C, Cahn JY, Delaunay J, Guyotat D, Deconinck E, Quesnel B, Stamatoullas A, Chomienne C, Degos L, Dombret H, Fenaux P, Ades L.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 2171.

Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Park S, Sapena R, Vassilieff D, Kelaidi C, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Ame S, Tertian G, Slama B, Fenaux P, Dreyfus F.
ASH, December 2010, Orlando
Blood (ASH Annual meeting Abstracts). 2010; 116: 2916.

Outpatient and Home Chemotherapy: Preliminary Results of the Experience of the Limousin (France) Hematological Care Network

Touati M, Remenieras L, Moreau S, Truffinet V, Lefort S, Vergnenegre F, Abouelfadel M, Lagarde A, Courmede A, Daulange A, **Laffetas MC, Bordessoule D.**

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 3823.

Treatment of Advanced CMML by Azacitidine (AZA) In a Compassionate Program. the GFM Experience In 38 Patients

Wolfromm A, Dreyfus F, Vey N, Delaunay J, Stamatoullas A, Banos A, Marfaing-Koka A, de Botton S, **Bordessoule D,** Legros L, Beyne Rauzy O, Gyan E, Cony Makhoul P, Thepot S, Itzykson R, Fenaux P, Ades L.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 4023.

Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs)

Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, Stamatoullas A, Choufi B, Delaunay J, **Gourin MP,** Cheze S, Ravoet C, Ferrant A, Escoffre-Barbe M, Aljasseem L, Raffoux E, Itzykson R, Ades L, Dreyfus F, Fenaux P.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 442.

Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial

Jaccard A, Leblond V, Royer B, Leleu X, Delarue R, Kolb B, Deconinck E, Stamatoullas A, Coppo P, Arnulf B, Hermine O, Moreau P, Fermanand JP.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 1344.

Validation of the Criteria of Response to Treatment In AL Amyloidosis

Palladini G, Dispenzieri A, Gertz MA, Wechalekar A, Hawkins P, O Schonland S, Hegenbart U, L. Comenzo R, Kastritis E, Dimopoulos M, **Jaccard A,** Klersy C, Merlini G.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 1364.

Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group

Ades L, Raffoux E, Chevret S, de Botton S, Guerci A, Pigneux A, Vey N, Lamy T, Huguette F, Muller B, Maloisel F, Deconinck E, Caillot D, Gratecos N, Sotto JJ, Ferrant A, **Turlure P,** Thomas X, Chevallier P, Ifrah N, Stamatoullas A, Chomienne C, Dombret H, Degos L, Fenaux P.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 13.

Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Ades L, ebras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Visanica S, **Turlure P,** Guerci A, Cabrol MP, Banos A, Blanc M, Ve Ny, Eclache V, Chevret S, Fenaux P.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 976.

Prognostic Impact of Wilms Tumor 1 Single Nucleotide Polymorphism rs16754 In Older Patients with Acute Myeloid Leukemia

Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C, Gardin C, Thomas X, **Turlure P,** Reman O, Berthon C, Dombret H, Castaigne S, Preudhomme C.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 2701

A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial

Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Recher C, Dartigeas C, Vey N, Legros L, Delaunay J, Salanoubat C, Visanica S, tamatoullas A, Isnard F, Marfaing-Koka A, De Botton S, Chelgoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Ades L, Fenaux P.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 3996.

Central Nervous System (CNS) at First Relapse In APL. A Report on 2 Multicenter Trials

Ferini GA, Raffoux E, Guerci A, Pigneux A, Huguet F, Vey N, Lamy T, Muller B, Chevallier P, Castaigne S, Turlure P, Ferrant A, Ifrah N, de Botton S, Dombret H, Ades L and Fenaux P.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 1084.

Azacitidine (AZA) In Relapsed MDS and AML After Allogeneic Stem Cell Transplantation (allo-HSCT): Results of the French ATU Program

Guièze R, Jouinot A, Itzykson R, Thepot S, Guillaume T, Coiteux V, Wittnebel S, de Botton S, Dartigeas C, Sirvent A, Turlure P, Bouscary D, Robin M, Vernant JP, Sutton L, Dreyfus F, Bay JO, Ades L, Fenaux P.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 1293.

A Pediatric Treatment of Ph-Negative Acute Lymphoblastic Leukemia (ALL) Is Effective and Safe In Adolescents and Young Adults (AYAs) until 29 Years of Age

Cluzeau T, Dhedin N, Huguet F, Raffoux E, Maury S, Lamy T, Mannone L, Guillerm G, Delannoy A, Turlure P, Norbert Vey N, Baruchel A, Dombret H, Boissel N

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 2125.

Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA)

Itzykson R, Thepot S, Beyne-Rauzy O, Quesnel B, Ame S, Turlure P, Harel S, Marfaing-Koka A, Chelgoum Y, Stamatoullas A, Uzunov M, Ifrah N, Dombret H, Lionel Ades L, S. Swern A, Gardin C, Fenaux P.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 2183.

AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM)

Fadlallah J, Bally C, Quesnel B, Vey N, Dreyfus F, Turlure P, de Botton S, Dartigeas C, de Renzis B, Thepot S, Itzykson R, Fenaux P, Ades L.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 2911.

Lack of Correlation of Endoscopy Findings and Pathological Results In GI-GvHD

Abraham J, Janin A, Gornet JM, Robin M, Peffault de Latour R, Ribaud P, Mary JY, Lemann M, Porcher R, Socie G.

ASH, December 2010, Orlando

Blood (ASH Annual meeting Abstracts). 2010; 116: 2339.

Left atrium enlargement is an independent predictor of overall mortality in patients with systemic amyloidosis

Mohty D, P. Pibarot P, Darodes N, Lavergne D, Echahidi N, Viot P, Bordessoule D, Jaccard A

Congrès international de cardiologie – 23-27 octobre 2010 – Montréal

Epidemiological review of lymphoma diagnosis in French rural area between 2003 and 2008

Touati M, Gourin MP, Abraham J, Weinbreck N, Gachard N, Olivrie-Gamaury A, Feuillard J, Jaccard A, Bordessoule D.

ASCO, Chicago 4-8 juin 2010

J Clin Oncol 2010, 28:15s, (suppl; abstr 18551)

Collégialité et responsabilité médicale, vers un élargissement de ces notions et une responsabilité partagée entre le médecin et son patient.

Trarieux-Signol S, Moreau S, Gourin MP, Bordessoule D

SFAP 2010 - Marseille juin 2010 - Communication orale

Référence CH24-d Regard des soignants d'un service d'hématologie clinique sur la loi relative aux droits des malades et à la fin de vie: analyse qualitative et quantitative

Trarieux-Signol S, Gourin MP, Guillout J, Vigier D, Penot A, Moreau S, Bordessoule D.

SFAP - Marseille juin 2010

Increased of overall survival (OS) and malignancies during tyrosine kinase inhibitors (TKI) in a real life cohort of patients with a chronic myeloid leukemia (CML).

Gourin MP, Turlure P, Gachard N, Girault S, Touati M, Abraham J, Pons E, Philippon C, Feuillard J, Bordessoule D.

ASCO, Chicago 4-8 juin 2010

J Clin Oncol 2010, 28:15s, (suppl; abstr 6602).

Effectiveness of second line treatment in AL amyloidosis patients refractory to M-Dex

Jaccard A, Abraham J, Debarri H, Penot A, Desport E, Aguilar C, Lavergne D, Auroy F, Leleu X, Goldstein A, Kolb B, Bridoux F, Femand JP, Leblond V.

12ème Congrès International de l'Amylose – 18-21 avril 2010 - Rome

Amyloid. 2010; 17: P-189.

Non invasive fibroscan detection of hepatic amyloidosis

Jaccard A, Cypierre A, Rousseau A, Yagoubi F, Abraham J, Lefebvre A, Loustaud-Ratti V;

12ème Congrès International de l'Amylose - 18-21 avril 2010 - Rome

Amyloid. 2010; 17 (suppl1) : P-162.

Systemic AL amyloidosis with renal involvement in a region of Western France

Eric Moumas, Estelle Desport, Jean-Marc Gombert, Corinne Lacombe, Jean-Michel Goujon, **Arnaud Jaccard**, Guy Touchard, Frank Bridoux

12ème Congrès International de l'Amylose - 18-21 avril 2010 - Rome

Amyloid. 2010; 17 (suppl1) : P-122.

Intérêt des bases de données pour améliorer les taux d'inclusion dans les protocoles de recherche clinique en hématologie.

Gourin MP, Marin B, Fargeas JB, Philippon C, Bompard F, Tisseuil C, Jaccard A, Preux PM, Bordessoule D.

Congrès 2010 de la Société Française d'Hématologie

Hématologie, 2010 (spécial 1) ; 16 : 223 [14-05]

Un réseau de psychologues ville-hôpital PsyHématolim autour du patient atteint d'hémopathie maligne : expérience d'une dérogation tarifaire en Limousin.

Touati M, Laffetas MC, Rampoux E, Aubert K, Truffinet V, Rapp MJ, Moreau S, Pechalat MP, Lefort S, Bordessoule D.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 222 [14-03]

La parole aux patients dans le réseau Hématolim : enquête de satisfaction sur les consultations avancées.

Touati M, Rapp MJ, Truffinet V, Venot J, VaquiLaffetas MC, Rampoux not S, Lo Re P, Henner G, Tardieux J, Gourin MP, Laffetas MC, Bordessoule D.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 221 [14-02]

Intérêt du rituximab dans le purpura thrombotique thrombocytopenique en réponse non optimale au traitement standard.

Froissard A, Veyradier A, Buffet M, Poullin P, Malot S, Galicier L, Bordessoule D, Vernant J, Azoulay E, Guidet B, Wynckel A, Coppo P.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 200 [12-40]

Facteurs pronostiques de réponse et de survie globale chez 271 SMD de haut risque (incluant des AREB-t) traités par azacytidine.

Itzykson R, Thépot S, Quesnel B, Beyne-Rauzy O, Dreyfus F, Turlure P, legros L, Dartigeas C, Delaunay J, Gardin C, Adès L, Fenaux P.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 160 [09-02]

Etude de phase I de l'anticorps monoclonal Anti-Natural Killer Inhibitory Receptor (KIR) IPH2101 en monothérapie dans la leucémie aiguë myéloïde du sujet âgé : effets cliniques et immunologiques d'une dose unique suivie d'injections répétées.

Vey N, Bourhis JH, Dombret H, Bordessoule D, Prébet T, Charbonnier A, de Botton S, Boissel N, d'Arnoux C, André P, Tiollier J, Squiban P, Blaise D, Olive D, Romagné F.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 137 [07-34]

Impact pronostique des mutations d'IDH1 et IDH2 dans les leucémies aiguës myéloblastiques à caryotype normal. Etude du groupe ALFA (Acute Leukemia French Association).

Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Bordessoule D, Pautas C, Terré C, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 120 [07-01]

Etude de phase II de l'association ACBVP + bortezomib dans le traitement de première ligne des lymphomes T ou à cellules NK : résultats définitifs du protocole GELA LNH05-1T.

Delmer A, Fitoussi O, Goulard P, Laurent G, Jaccard A, Morschhauser F, Ferme C, Tilly H, Gisselbrecht C, Coiffier B.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : p 84 [05-60]

Lymphomes non hodgkiniens et diabète de type 2 chez les sujets âgés : impact sur la prise en charge dans la vraie vie.

Moreau S, Gourin MP, Remenieras L, Touati M, Bompard F, Olivrie A, Weinbreck N, Lefort S, Devesa-Mansour D, Feuillard J, Jaccard A, Bordessoule D.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 82 [05-56]

Résultats préliminaires de l'intérêt de la tomoscintigraphie au MIBI pour la prédiction de la réponse à la chimiothérapie lors du bilan initial des lymphomes de haut grade et des maladies de Hodgkin : à propos d'une étude prospective de 81 patients.

Gourin MP, Monteil J, Marin B, **Girault S**, **Dmytruk N**, **Abraham J**, **Olivrie-Gamaury A**, Weinbreck N, **Jaccard A**, **Feuillard J**, **Bordessoule D**.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 71 [05-35]

Traitement séquentiel par rituximab puis CHOP+G-CSF des lymphoproliférations post-transplantation : résultats de l'étude de phase II multicentrique prospective européenne « LPT1 ».

Choquet S, Oertel S, Leblond V, Morschhauser F, Lamy T, **Jaccard A**, Salles G, Bouabdallah R, Suarez F, Lebranchu Y, Vande E, Trappe RU.

Congrès 2010 de la Société Française d'Hématologie
Hématologie, 2010 (spécial 1) ; 16 : 56 [05-04]

La réflexion collective sur le sens du soin : une dimension essentielle en hématologie

Bordessoule D.

Congrès 2010 de la Société Française d'Hématologie. Communication orale

✓ Remerciements pour participation comme centre investigateur

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).

N Engl J Med. 2010, 363(26):2511-2.

Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission.

Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F, de Witte T, Meloni G, Attal M, Bernal T, Rocha V; Acute Leukemia Working Party, European Cooperative Group for Blood and Marrow Transplantation.

Blood. 2010, 116(17):3157-62.

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.

Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter JB; EPIC study investigators.

Blood. 2010, 116(14):2448-54.

B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease.

Mouillot G, Carmagnat M, Gérard L, Garnier JL, Fieschi C, Vince N, Karlin L, Viillard JF, Jaussaud R, Boileau J, Donadieu J, Gardembas M, Schleinitz N, Suarez F, Hachulla E, Delavigne K, Morisset M, Jacquot S, Just N, Galicier L, Charron D, Debré P, Oksenhendler E, Rabian C; DEFI Study Group.

J Clin Immunol. 2010, 30(5):746-55.

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.

Morel P, Munck JN, Coiffier B, Gisselbrecht C, Ranta D, Bosly A, Tilly H, Quesnel B, Thyss A, Mounier N, Brière J, Molina T, Reyes F; Groupe d'Etude de Lymphomes des l'Adulte (GELA).

Leuk Lymphoma. 2010, 51(9):1668-77.

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators. Leuk Res. 2010, 34(9):1143-50.

The French national registry of primary immunodeficiency diseases.

CEREDIH: The French PID study group.

Clin Immunol. 2010, 135(2):264-72.

HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians.

Coppo P, Busson M, Veyradier A, Wynckel A, Poullin P, Azoulay E, Galicier L, Loiseau P; French Reference Centre For Thrombotic Microangiopathies.

J Thromb Haemost. 2010, 8(4):856-9.

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, Duval A, Schved JF, Fischer AM, Socié G; French Society of Hematology.

Haematologica. 2010, 95(4):574-81.